Table 2 Primary endpoint: mean worst EAPP and absolute change from baseline to end of intervention (measured daily on the NRS as ESD item 1)—primary per-protocol set
Timepoint | Â | Eliapixant 25Â mg BID | Eliapixant 75Â mg BID | Eliapixant 150Â mg BID | Placebo | Total |
|---|---|---|---|---|---|---|
Baseline | n | 31 | 31 | 31 | 30 | 123 |
| Â | Missing | 0 | 0 | 0 | 0 | 0 |
| Â | Mean (SD) | 6.40 (1.66) | 6.13 (1.77) | 6.95 (1.38) | 6.14 (1.96) | 6.41 (1.72) |
| Â | Median | 6.68 | 6.25 | 6.96 | 5.74 | 6.62 |
| Â | Q1, Q3 | 5.27, 7.44 | 4.86, 7.46 | 6.19, 7.86 | 4.56, 7.64 | 5.12, 7.58 |
| Â | Min, max | 3.1, 9.6 | 3.0, 9.6 | 3.8, 9.9 | 2.6, 10.0 | 2.6, 10.0 |
Week 12 (EOI) | n | 24 | 22 | 20 | 26 | 92 |
| Â | Missing | 7 | 9 | 11 | 4 | 31 |
| Â | Mean (SD) | 4.57 (2.10) | 4.15 (2.49) | 5.15 (2.42) | 4.29 (1.71) | 4.52 (2.17) |
| Â | Median | 4.61 | 3.91 | 4.86 | 3.95 | 4.18 |
| Â | Q1, Q3 | 3.15, 5.99 | 1.61, 6.54 | 3.30, 7.13 | 3.08, 5.80 | 3.09, 6.13 |
| Â | Min, max | 0.5, 8.5 | 0.6, 8.6 | 0.5, 10.0 | 1.5, 8.3 | 0.5, 10.0 |
Change from baseline | n | 24 | 22 | 20 | 26 | 92 |
| Â | Missing | 7 | 9 | 11 | 4 | 31 |
|  | Mean (SD) | –1.56 (1.35) | –2.12 (2.66) | –1.88 (2.03) | –1.89 (1.91) | –1.86 (2.00) |
|  | Median | –1.36 | –1.39 | –1.30 | –1.67 | –1.40 |
|  | Q1, Q3 | –2.13, − 0.50 | –3.29, − 0.17 | –3.46, − 0.19 | –3.04, − 0.39 | –3.01, − 0.35 |
|  | Min, max | –4.1, 0.4 | –7.9, 1.9 | –6.2, 1.6 | –6.3, 1.3 | –7.9, 1.9 |